

**Registered Charity Number:265985**

**CANCER PREVENTION RESEARCH TRUST**

**REPORT AND FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2024**

**CANCER PREVENTION RESEARCH TRUST**  
**REPORT AND FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2024**

**CONTENTS**

| DESCRIPTION                       | PAGE NO. |
|-----------------------------------|----------|
| TRUST INFORMATION                 | 2        |
| TRUSTEES ANNUAL REPORT            | 3 – 6    |
| INDEPENDENT EXAMINER’S REPORT     | 7        |
| STATEMENT OF FINANCIAL ACTIVITIES | 8        |
| BALANCE SHEET                     | 9        |
| STATEMENT OF CASH FLOWS           | 10       |
| NOTES TO THE ACCOUNTS             | 11 – 18  |

## **CANCER PREVENTION RESEARCH TRUST**

### **TRUST INFORMATION FOR THE YEAR ENDED 30 JUNE 2024**

---

Trustees: Mr. R. O'Connor  
Mr. K. Shanshol

Registered Charity Number: 265985

Place of Business: Cobden House  
231 Roehampton Lane  
London  
SW15 4LB

Accountants: Ossmans Ltd  
Chartered Accountants  
591 London Road  
Cheam  
Sutton  
Surrey  
SM3 9AG

Solicitors: Russell-Cooke  
7 Putney Hill  
London  
SW15 6AB

Bankers: NatWest  
P.O. Box 13309  
134 Aldersgate Street  
London  
EC1A 4AJ

## **CANCER PREVENTION RESEARCH TRUST**

### **TRUST INFORMATION FOR THE YEAR ENDED 30 JUNE 2024**

---

The Trustees present their report with the financial statements for the year ended 30<sup>th</sup> June 2024.

#### **Principal activities**

The principal activities of the trust during the year were to raise money in order to continue with its principal objectives. These objectives are to advance medical research and, in particular, research into the prevention of cancer oncogenesis and associated malignant diseases, and to publish the results of such research.

#### **Aims of the Trust**

The objective of the Trust is to create grants for leading edge research in the UK for cancer prevention. We believe action to prevent the onset of cancer in patients before they are admitted to hospital may be more productive in reducing the spread of the disease, as opposed to investment in the use of post-diagnosis medicines.

The Trustees confirm that they have referred to the Charity Commission's guidance on public benefit in planning future activities and objectives.

#### **Main activities of the Trust**

- a) Searching the latest scientific research on Cancer Prevention-related literature;
- b) Allocating funds to cancer projects progressing the science of Cancer Prevention;
- c) Running a local fund-raising shop selling second-hand produce maintaining contact with the local community;
- d) Running an office of two Trustees and four staff; and
- e) Producing an information Newsletter on latest scientific developments in cancer prevention to our growing number of donors.

#### **Performance Monitoring**

- a) Having a strong relationship with our accountant to maximize financial stability; and
- b) Building a good relationship with our donors and responding to their suggestions, and always keen to observe positive feedback.

Success is measured by the income generated from our present internet advertising campaign, and the outcomes of Scientific Research program conducted by Medical Research teams who have received our grants generated by advertising. We hope to keep all Trust expenditure, salaries and building maintenance less than 4%, advertising 24% and grants given out to our Cancer Research Teams to be 72% of all income.

## **CANCER PREVENTION RESEARCH TRUST**

### **TRUST INFORMATION FOR THE YEAR ENDED 30 JUNE 2024**

---

#### **Review of year**

The Trust provides information to the public on cancer prevention, as well as supporting research at teaching hospitals and other establishments.

During the year the Trust received £797,197.00 in donations and legacies (2023 - 472,548.00). It provided £700,000.00 grants (2023 - £324,000.00) to universities for medical research, and in the current year, this was allocated between the following universities: University of East Anglia £250,000, University of Manchester £150,000.00, University of Oxford £100,000 and University of Leicester £200,000.00.

The Trust continues to publish its Newsletter "Cancer Prevention and Health News". The Trust advertises by use of the website <https://www.cancerpreventionresearch.co.uk/>, Lecture Note for Solicitor's magazine, Yell on-line directory and the Newsletter.

We have recently increased our internet presence.

One of the research projects we funded has received an award in 2017 and some other projects were published and received acknowledgement in peer reviewed well respected scientific papers.

#### **Reserves**

The Trust holds reserves of £2,828,065.00 (2023 – 2,977,132.00). Of these reserves, £479,868.00 (2023 - £480,492.00) is employed in providing the Trust with property and tangible assets for the operation of the Trust's activities. The balance of the Trust's reserves is being accumulated for the planned construction of a Laboratory at Cobden House.

#### **Grants Policy**

We search the latest scientific papers at UK universities and offer grants support where we see key research projects relevant to a preventative approach to cancer reduction in the population. There have been three main universities benefitting from our grants, namely, East Anglia, Leicester, Oxford and Manchester.

#### **Volunteers**

Presently, there are two volunteers running our local shop.

#### **Investment Policy**

The Charity operates an investment policy that carries low risk.

## **CANCER PREVENTION RESEARCH TRUST**

### **TRUST INFORMATION FOR THE YEAR ENDED 30 JUNE 2024**

---

#### **Fund Raising Policy**

The principal source of income is from legacies and donations generated through on-line advertising.

The Trust is successful in raising income from internet marketing and we do expect material expenditure associated with this activity to have a positive impact on current and future fundraising.

#### **Risks**

Due to fluctuations in legacies, there could be a period in which less money is collected by the Trust. This could potentially put keeping up our payments at risk. However, to ensure the prevention of this, sufficient money is held back in reserve to meet these commitments. Furthermore, to keep a balance, we are trying to increase other means of raising funds through other forms of donations and by selling goods in our shops.

A decrease in donations and legacies we receive from the public could affect future financial performance, and thus have consequences on the fulfilment of the Charity's objectives.

#### **Future Plans**

To consolidate our internet profile.

Make our contact with the public more interactive using Mobile phone applications on self-monitoring (looking for very early cancer signs).

The Trust plans to maintain grants awarded in future periods to meet the target of 40% of income.

The planned construction of the laboratory at Cobden House is on hold due to the construction of residential properties adjacent to the planned construction site. There are restricted funds of £1,740,707.00 at the year-end held for this purpose.

#### **Structure, governance and management**

The Charity is a registered charity, number 265985, registered with the Charities Commission. The Charity is controlled by its Trust Deed and constitutes an unincorporated charity.

#### **Organization Structure**

The Charity makes decisions through discussions with all the Trust staff and Trustees by brainstorming sessions, and then by advice from our Legal and Financial advisors. Structural steps for decisions are: meetings with staff; legal and financial advisor meetings; minute meetings; and then action.

## **CANCER PREVENTION RESEARCH TRUST**

### **TRUST INFORMATION FOR THE YEAR ENDED 30 JUNE 2024**

---

#### **Recruitment and Training Policy**

The Trustees will internally advertise all vacant positions to current staff and volunteers to enable career advancements and increased participation. The prime trustee has the authority to appoint new trustees. The Trust aims to provide a framework for training and development that ensures staff have the necessary competencies to deliver the Trust strategy. Trustee training is achieved by access to gov.uk charity guidance and in-house workshops held by solicitors Russell-Cooke.

#### **Trustees**

No trustees are remunerated by the Trust.

#### **Trustees' Responsibilities**

Current legislation requires Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the Trust and of the surplus or deficit for that period.

In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and apply them consistently;
- Observe the methods and principles in Charities SORP 2019 (FRS 102);
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in accounts; and
- Prepare the financial statements on the going concern basis, unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Trust and, hence, for taking reasonable steps for the prevention and detection of fraud and other irregularities.

#### **Statement of disclosure of information to the Independent Examiner**

So far as the trustees are aware, there is no relevant information of which the charity's accountants are unaware and each trustee has taken all the steps that he or she ought to have as a trustee in order to make himself or herself aware of any relevant information and to establish that the Charity's accountants are aware of that information.

The report was approved by the Board of Trustees on 25 April 2025 and signed by:

.....  
Trustee Mr. R O'Connor

.....  
Trustee Mr. K. Shanshol

## **CANCER PREVENTION RESEARCH TRUST**

### **INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES YEAR ENDED 30 JUNE 2024**

---

I report on the accounts of the Trust for the year ended 30 June 2024, which are set out on pages 8 to 10.

#### **Respective responsibilities of Trustees and Examiner**

The Charity's trustees are responsible for the preparation of the accounts. The Charity's trustees consider that an audit is not required for this under Section 144(2) of the Charities Act 2011 and that an independent examination is needed.

It is my responsibility to:

- a) Examine the accounts under Section 145 of the 2011 Act;
- b) Follow the procedures laid down in the general directions given by the Charity Commission under Section 145(5)(b) of the 2011 Act; and
- c) State whether particular matters have come to my attention.

#### **Basis of Independent Examiner's Report**

My examination was carried out in accordance with the general directions given by the Charity Commission. An examination includes a review of the accounting records kept by the Charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and, consequently, no opinion is given as to whether the accounts present a "true and fair view" and the report is limited to those matters set out in the statement below.

#### **Independent Examiner's Statement**

In connection with my examination, no matter has come to my attention which gives me reasonable cause to believe that all material respects the requirements:

'to keep accounting records in accordance with Section 130 of the 2011 Act, and to prepare accounts which accord with the accounting records and comply with the accounting requirements of the 2011 Act' have been met.

Ossmans Ltd  
Chartered Accountants  
591 London Road  
Cheam  
Sutton  
SM3 9AG

25 April 2025



**CANCER PREVENTION RESEARCH TRUST**

STATEMENT OF FINANCIAL ACTIVITIES  
YEAR ENDED 30 JUNE 2024

|  | Unrestricted<br>Funds 2024<br>£ | Restricted<br>Funds 2024<br>£ | Total<br>Funds 2024<br>£  | Total<br>Funds 2023<br>£ |
|--|---------------------------------|-------------------------------|---------------------------|--------------------------|
| <b>Income</b>                              |                                 |                               |                           |                          |
| <b>Donations &amp; Legacies</b>            |                                 |                               |                           |                          |
| Donations received                         | 25,912                          | -                             | 25,912                    | 125,802                  |
| Legacies received                          | 772,096                         | -                             | 772,096                   | 346,746                  |
| <b>Income from charitable activities</b>   |                                 |                               |                           |                          |
| Sales of donated goods                     | 15,013                          | -                             | 15,013                    | 3,894                    |
| Investment income                          | <u>0</u>                        | <u>25,732</u>                 | <u>25,732</u>             | <u>10,720</u>            |
| Rent income                                | <u>24,750</u>                   | <u>0</u>                      | <u>24,750</u>             | <u>0</u>                 |
| <b>Total income</b>                        | <b><u>837,771</u></b>           | <b><u>25,732</u></b>          | <b><u>863,503</u></b>     | <b><u>495,412</u></b>    |
| <b>Expenditure on</b>                      |                                 |                               |                           |                          |
| Fund raising and publicity                 | (41,889)                        | -                             | (41,889)                  | (54,787)                 |
| Charitable activities                      | <u>(971,774)</u>                | -                             | <u>(971,774)</u>          | <u>(649,215)</u>         |
| <b>Total Expenditure</b>                   | <b><u>(1,013,663)</u></b>       | <b><u>-</u></b>               | <b><u>(1,013,663)</u></b> | <b><u>(704,002)</u></b>  |
| Other interest receivable and other income | 561                             | -                             | 561                       | 993                      |
| Net gains/(loss) on investments            | -                               | <u>532</u>                    | 532                       | 357                      |
| <b>Net movement of funds</b>               | <b><u>(175,331)</u></b>         | <b><u>26,264</u></b>          | <b><u>(149,067)</u></b>   | <b><u>(207,240)</u></b>  |
| <b>Reconciliation of funds</b>             |                                 |                               |                           |                          |
| Total funds brought forward                | 1,262,689                       | 1,714,443                     | 2,977,132                 | 3,184,372                |
| Net movement of funds                      | <u>(175,331)</u>                | <u>26,264</u>                 | <u>(149,067)</u>          | <u>(207,240)</u>         |
| Total funds carried forward                | <u>1,087,358</u>                | <u>1,740,707</u>              | <u>2,828,065</u>          | <u>2,977,132</u>         |

All the activities of the company are from continuing operations.

**CANCER PREVENTION RESEARCH TRUST**  
**STATEMENT OF FINANCIAL POSITION**  
**AS AT 30 JUNE 2024**

|   |             | <b>2024</b>      |                  | <b>2023</b>      |                  |
|---|-------------|------------------|------------------|------------------|------------------|
|   | <b>Note</b> | <b>£</b>         | <b>£</b>         | <b>£</b>         | <b>£</b>         |
| <b>Fixed assets</b>                                   |             |                  |                  |                  |                  |
| Tangible assets                                       | <b>2</b>    | 479,868          |                  | 480,492          |                  |
| Investments   | <b>3</b>    | <u>2,348</u>     |                  | <u>1,816</u>     |                  |
|   |             |                  | 482,216          |                  | 482,308          |
| <b>Current assets</b>                                 |             |                  |                  |                  |                  |
| Debtors   | <b>4</b>    | 2,282            |                  | 257              |                  |
| Cash at bank and in hand                              |             | <u>2,363,106</u> |                  | <u>2,520,318</u> |                  |
|   |             |                  | 2,365,388        |                  | 2,520,575        |
| <b>Creditors: amounts falling due within one year</b> | <b>5</b>    |                  | <u>(19,539)</u>  |                  | <u>(25,751)</u>  |
| <b>Total assets</b>                                   |             |                  | <u>2,847,604</u> |                  | <u>3,002,883</u> |
| <b>Total assets less current liabilities</b>          |             |                  | <u>2,828,065</u> |                  | <u>2,977,132</u> |
| <b>Capital and reserves</b>                           |             |                  |                  |                  |                  |
| Income and expense account                            | <b>11</b>   |                  | <u>2,828,065</u> |                  | <u>2,977,132</u> |
| <b>Total funds</b>                                    |             |                  | <u>2,828,065</u> |                  | <u>2,977,132</u> |

These financial statements were approved by the board of trustees and authorized to issue on 25 April 2025, and are signed on behalf of the board by:

.....  
Trustee Mr. R O'Connor

.....  
Trustee Mr. K. Shanshol

**CANCER PREVENTION RESEARCH TRUST**  
**STATEMENT OF CASH FLOW**  
**YEAR ENDED 30 JUNE 2024**

|   | 2024                    | 2023                    |
|---|-------------------------|-------------------------|
|   | £                       | £                       |
| <b>Cash flows from operating activities</b>             |                         |                         |
| Cash absorbed by operations (Note 12)                   | <b><u>(202,275)</u></b> | (197,693)               |
| Cash flows from investing activities                    |                         |                         |
| Sales of PPE  | 15,269                  |                         |
| Purchase PPE  | (20,688)                | (3,527)                 |
| <b>Dividends, interest and rents from investments</b>   | <b><u>50,482</u></b>    | <u>10,720</u>           |
| <b>Net cash from investing activities</b>               | <b>45,063</b>           | <b>7,193</b>            |
| Net decrease in cash and cash equivalents               | (157,212)               | (190,500)               |
| Cash and cash equivalents at beginning of the year      | <u>2,520,318</u>        | <u>2,710,818</u>        |
| <b>Cash and cash equivalents at the end of the year</b> | <b><u>2,363,106</u></b> | <b><u>2,520,318</u></b> |
| Components of cash and cash equivalents                 |                         |                         |
| <b>Cash and bank balance</b>                            | <b><u>2,363,106</u></b> | <b><u>2,520,318</u></b> |

## **CANCER PREVENTION RESEARCH TRUST**

### **NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 30 JUNE 2024**

---

#### **1 Accounting policies**

##### **Basis of preparation**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) – Charities SORP (FRS 102) (effective 1 January 2019) and the Charities Act 2011. The accounts (financial statement) have been prepared under the historical cost convention with items recognized at cost or transaction value unless otherwise stated in the relevant note(s) to these accounts.

The Trust constitutes a public benefit entity as defined by FRS 102.

The accounts are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £1.

##### **Going concern**

The accounts are prepared on a going concern basis.

##### **Income**

Income is included in the Statement of Financial Activities (SoFA) when the Charity becomes entitled to, and virtually certain to receive, the income, and the amount of the income can be measured with sufficient reliability. Legacy gifts are recognized on a case by case basis following the grant of probate when the administrator/executor for the estate has communicated in writing both the amount and the settlement date. Voluntary income received by way of grants, donations and gifts is included in the SoFA when receivable and only when the Charity has unconditional entitlement to the income. The Trust recognized income from goods on sale.

##### **Expenditure**

Recognized expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates. Expenditure on raising funds comprise the cost associate with attracting voluntary income fundraising cost and investment management costs. Expenditure on charitable activities comprise the cost incurred by the Charity in the delivery of its activities and services in the furtherance of its objectives, including the making of grants and governance costs.

## **CANCER PREVENTION RESEARCH TRUST**

### **NOTES TO THE FINANCIAL STATEMENTS (continued)** **YEAR ENDED 30 JUNE 2024**

---

#### **1 Accounting Policies (continued)**

##### **Expenditure (continued)**

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the Charity, including the independent examination fees, costs linked to the strategic management of the Charity, together with the share of other administration costs.

Grants payable are payments made to third parties in the furtherance of the charitable objectives of the Trust. In case of an unconditional grant offer, this is accrued once the recipient has been notified of the grant award. Provisions for grants are made when the intention to make a grant has been communicated to the grant recipient but there is uncertainty as to the meeting of the grant terms.

##### **Taxation**

The Charity is exempt from tax on its charitable activities.

##### **Depreciation**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life:

|                         |                               |
|-------------------------|-------------------------------|
| Plant and machinery     | 25% on reducing balance basis |
| Furniture and equipment | 25% on reducing balance basis |
| Motor van               | 25% on reducing balance basis |

Depreciation charge in the year of acquisition and not in the year of disposal.

The Trustees are of the opinion that no depreciation is charged on the freehold properties.

##### **Debtors**

Prepayments are valued at the amount prepaid net of any trade discounts due.

##### **Cash and cash equivalents**

Cash and cash equivalents comprise at bank and in hand, demand deposits with banks and other short-term highly liquid investments, with original maturities of three months or less, and bank overdrafts. In the statement of financial position, bank overdrafts are shown within creditors. In the Statement of Cash Flows, cash and cash equivalents are shown net of bank overdrafts that are repayable on demand and form an integral part of the trust cash management.

## **CANCER PREVENTION RESEARCH TRUST**

### **NOTES TO THE FINANCIAL STATEMENTS (continued)** **YEAR ENDED 30 JUNE 2024**

---

#### **1 Accounting Policies (continued)**

##### **Creditors and provisions**

Creditors and provisions are recognized where the charity has obligations resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognized at their settlement amount after allowing for any trade discounts due.

##### **Investments policy**

Investments are a form of basic financial instrument and are initially recognized at their transaction value and subsequently measured at their fair value as at their balance sheet date using the closing quoted market price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

##### **Realized gains and losses**

All gains and losses are taken to the Statement of Financial Activities as they arise. Realized gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealized gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realized and unrealized investment gains and losses are combined in the Statement of Financial Activities.

##### **Pension Costs**

The Charity operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the charity pays fixed contributions into a separate entity. Once the contributions have been paid the charity has no further payments obligations. The contributions are recognized as expenses when they fall due. Amounts not paid are shown in accruals in the balance sheet. The assets of the plan are held separately from the charity in independently administered funds.

##### **Funds**

Restricted funds are funds which are to be used in accordance with specifications imposed by the donor or trust deed. There is a single restricted fund (Cobden House Fund) earmarked for the construction of the Laboratory at Cobden House.

Unrestricted income funds comprise those funds which the trustees are free to use for any purpose in furtherance of the charitable objectives. Unrestricted funds include designated funds where the trustees, at their discretion, have created a fund for a specific purpose.

**CANCER PREVENTION RESEARCH TRUST**

NOTES TO THE FINANCIAL STATEMENTS (continued)  
YEAR ENDED 30 JUNE 2024

**2 Tangible assets**

|                        | Freehold<br>property | Plant and<br>machinery | Motor vehicle | Fixtures,<br>fittings and<br>equipment | <b>Total</b>   |
|------------------------|----------------------|------------------------|---------------|--|----------------|
|                        | £                    | £                      | £             | £                                      | £              |
| <b>Cost</b>            |                      |                        |               |  |                |
| At 1 July 2023         | 449,294              | 75,555                 | 42,002        | 29,046                                 | 595,897        |
| Additions              |                      |                        | 20,688        |  | 20,688         |
| Disposal               |                      |                        | (19,769)      |  | (19,769)       |
| <b>At 30 June 2024</b> | <u>449,294</u>       | <u>75,555</u>          | <u>42,921</u> | <u>29,046</u>                          | <u>596,816</u> |
| <b>Depreciation</b>    |                      |                        |               |  |                |
| At 1 July 2023         | -                    | 68,497                 | 18,376        | 28,532                                 | 115,405        |
| Charge for the year    | -                    | 1,765                  | 8,299         | 128                                    | 10,192         |
| Disposal               |                      |                        | (8,649)       |  | (8,649)        |
| <b>At 30 June 2024</b> | -                    | <u>70,262</u>          | <u>18,026</u> | <u>28,660</u>                          | <u>116,948</u> |
| <b>Carrying amount</b> |                      |                        |               |  |                |
| <b>At 30 June 2024</b> | <u>449,294</u>       | <u>5,293</u>           | <u>23,856</u> | <u>386</u>                             | <u>479,868</u> |
| At 30 June 2023        | <u>449,294</u>       | <u>7,058</u>           | <u>23,626</u> | <u>514</u>                             | <u>480,492</u> |

**3 INVESTMENTS**

|  | Ordinary shares in listed<br>investments at market<br>value | <b>Total</b> |
|--|---|--------------|
|  | £   | £            |
| <b>Cost</b>                            |   |              |
| At 1 July 2023                         | 1,816   | 1,816        |
| Fair value adjustment                  | 532   | 532          |
| <b>At 30 June 2024</b>                 | <u>2,348</u>  | <u>2,348</u> |
| <b>Impairment</b>                      |   |              |
| <b>At 1 July 2023 and 30 June 2024</b> | -   | -            |
| <b>Carrying amount</b>                 |   |              |
| <b>At 30 June 2024</b>                 | <u>2,348</u>  | <u>2,348</u> |
| At 30 June 2024                        | <u>1,816</u>  | <u>1,816</u> |

# CANCER PREVENTION RESEARCH TRUST

## NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 30 JUNE 2024

### 4 DEBTORS

|               | 2024         | 2023       |
|---------------|--------------|------------|
|               | £            | £          |
| Other debtors | 693          | -          |
| Prepayments   | <u>1,589</u> | <u>257</u> |
|               | <b>2,282</b> | <b>257</b> |

### 5 CREDITORS

|  | 2024          | 2023          |
|--|---------------|---------------|
|  | £             | £             |
| <b>Amounts falling due within one year</b> |               |               |
| Rent advance                               | 8,250         | 8,250         |
| Social security and other taxes            | 3,189         | 3,334         |
| Other creditors                            | <u>8,100</u>  | <u>14,167</u> |
|  | <b>19,539</b> | <b>25,751</b> |

### 6 ANALYSIS OF CHARITABLE EXPENDITURE

|                        | 2024           | 2023           |
|------------------------|----------------|----------------|
|                        | £              | £              |
| Staff costs            | 147,113        | 135,184        |
| Grants awards          | 700,000        | 324,000        |
| Vehicles expenses      | 11,891         | 8,342          |
| Property expenses      | 86,445         | 151,756        |
| Insurance              | 5,485          | 5,317          |
| Depreciation           | 10,192         | 10,399         |
| Other costs            | 5,248          | 3,627          |
| Legal and professional | -              | 5,190          |
| Accountancy fees       | <u>5,400</u>   | <u>5,400</u>   |
|                        | <b>971,774</b> | <b>649,215</b> |

### 7 ANALYSIS OF GRANTS

In the year, the following grants were made to institutions for medical research:

|                           | 2024           | 2023           |
|---------------------------|----------------|----------------|
|                           | £              | £              |
| University of East Anglia | 250,000        | 90,500         |
| University of Manchester  | 150,000        | 140,500        |
| University of Leicester   | 200,000        | 93,000         |
| University of Oxford      | <u>100,000</u> | <u>-</u>       |
|                           | <b>700,000</b> | <b>324,000</b> |



# CANCER PREVENTION RESEARCH TRUST

## NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 30 JUNE 2024

### 8 ANALYSIS OF STAFF COST AND REMUNERATION

|                       | 2024           | 2023           |
|-----------------------|----------------|----------------|
|                       | £              | £              |
| Salaries and wages    | 122,822        | 112,000        |
| Social security costs | 12,631         | 12,024         |
| Other pension cost    | <u>11,660</u>  | <u>11,160</u>  |
|                       | <u>147,113</u> | <u>135,184</u> |

The average number of employees during the year 2024 - 4 (2023 – 3) with all employees providing either support to the governance of the Charity, or support services to charitable activities. No employees received total employee benefits of more than £60,000.00.

### 9 RELATED PARTY

No remuneration was paid to the trustees in the year 2024 (2023 - Nil).

### 10 ANALYSIS OF NET ASSETS BETWEEN FUNDS

|                       | Unrestricted funds<br>£ | Restricted funds<br>£ | Total<br>£       |
|-----------------------|-------------------------|-----------------------|------------------|
| Current year          |                         |                       |                  |
| Fixed assets          | 479,868                 | 2,348                 | 482,216          |
| Net current assets    | 607,490                 | 1,738,359             | 2,345,849        |
| Long term liabilities | <u>0</u>                | <u>0</u>              | <u>0</u>         |
|                       | <u>1,087,358</u>        | <u>1,740,707</u>      | <u>2,828,065</u> |
| Prior year            |                         |                       |                  |
| Fixed assets          | 487,492                 | 1,816                 | 482,308          |
| Net current assets    | 782,197                 | 1,712,627             | 2,494,824        |
| Long term liabilities | <u>0</u>                | <u>0</u>              | <u>0</u>         |
|                       | <u>1,262,689</u>        | <u>1,714,443</u>      | <u>2,977,132</u> |

Restricted funds are made up of the Cobden House Fund earmarked for the construction of the Laboratory at Cobden House.

# CANCER PREVENTION RESEARCH TRUST

## NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 30 JUNE 2024

### 11 ANALYSIS OF MOVEMENTS IN FUNDS

| <b>Current year</b>                   | Balance<br>1.7.2023<br>£ | Income<br>£           | Expenditure<br>£          | Gains/losses<br>£   | Balance<br>30.6.2024<br>£ |
|---------------------------------------|--------------------------|-----------------------|---------------------------|---------------------|---------------------------|
| Unrestricted funds                    | 1,262,689                | 837,771               | (1,013,663)               | 561                 | 1,087,358                 |
| Restricted funds<br>Cobden House fund | <u>1,714,443</u>         | <u>25,732</u>         | -                         | <u>532</u>          | <u>1,740,707</u>          |
|                                       | <b><u>2,977,132</u></b>  | <b><u>863,503</u></b> | <b><u>(1,013,663)</u></b> | <b><u>1,093</u></b> | <b><u>2,828,065</u></b>   |
| <b>Prior year</b>                     | Balance<br>1.7.2022<br>£ | Income<br>£           | Expenditure<br>£          | Gains/losses<br>£   | Balance<br>30.6.2023<br>£ |
| Unrestricted funds                    | 1,481,006                | 484,692               | (704,002)                 | 993                 | 1,262,689                 |
| Restricted funds<br>Cobden House Fund | <u>1,703,366</u>         | <u>10,720</u>         | -                         | <u>357</u>          | <u>1,714,443</u>          |
|                                       | <b><u>3,184,372</u></b>  | <b><u>494,212</u></b> | <b><u>(704,002)</u></b>   | <b><u>1,350</u></b> | <b><u>2,977,132</u></b>   |

### 12 CASH GENERATED FROM OPERATIONS

|   | 2024<br>£               | 2023<br>£               |
|---|-------------------------|-------------------------|
| <b>Cash flows from operating activities</b> |                         |                         |
| Profit/(loss) for the financial year        | (149,067)               | (207,240)               |
| <b>Adjustments for:</b>                     |                         |                         |
| Depreciation                                | 10,192                  | 10,399                  |
| Gain on disposal assets                     | (4,149)                 |                         |
| Investment income                           | (50,482)                | (10,720)                |
| Gain on investment                          | (532)                   | (357)                   |
| Interest income                             |                         |                         |
| <b>Movement in working capital:</b>         |                         |                         |
| (Increase)/decrease in debtors              | (2,025)                 | (159)                   |
| Increase/(decrease) in creditors            | (6,212)                 | 10,384                  |
| <b>Net cash used operating activities</b>   | <b><u>(202,275)</u></b> | <b><u>(197,693)</u></b> |

**CANCER PREVENTION RESEARCH TRUST**

**STATEMENT OF FINANCIAL STATEMENTS**

**YEAR ENDED 30 JUNE 2024**

|  | <b>2024</b>             | <b>2023</b>             |
|--|-------------------------|-------------------------|
|  | <b>£</b>                | <b>£</b>                |
| <b>INCOME</b>                            |                         |                         |
| Donations                                | 25,912                  | 125,802                 |
| Legacies                                 | 772,096                 | 346,746                 |
| Sales of donated goods                   | 15,013                  | 3,894                   |
| Interest received                        | 25,732                  | 10,720                  |
| Rent income                              | 24,750                  | 8,250                   |
|  | <b><u>863,503</u></b>   | <b><u>495,412</u></b>   |
| Other income                             | 561                     | 993                     |
|  | <b><u>864,064</u></b>   | <b><u>496,405</u></b>   |
| <b>EXPENDITURE</b>                       |                         |                         |
| Staff salaries and pensions              | 147,113                 | 135,184                 |
| Grants                                   | 700,000                 | 324,000                 |
| Advertising                              | 41,889                  | 54,787                  |
| Printing, postage and stationery         | 170                     | 230                     |
| Light and heat                           | 3,371                   | 2,285                   |
| Telephone and Internet                   | 4,558                   | 3,560                   |
| Rates and Water                          | 7,111                   | 6,122                   |
| Legal and Professional                   | 0                       | 5,190                   |
| Accountancy                              | 5,400                   | 5,400                   |
| Repairs and maintenance, Renewals        | 62,723                  | 131,400                 |
| Insurance                                | 5,485                   | 5,317                   |
| Cleaning                                 | 6,695                   | 6,031                   |
| Computer and equipment costs             | 1,816                   | 2,130                   |
| Bank charges and interest                | 430                     | 412                     |
| Sundries                                 | 1,181                   | 759                     |
| Subscriptions                            | 3,638                   | 2,454                   |
| Motor expense                            | 16,040                  | 8,342                   |
| Gain on revaluation of investments       | (532)                   | (357)                   |
| Gain on disposal of tangible assets      | (4,149)                 | 0                       |
| Depreciation of tangible assets          | 10,192                  | 10,399                  |
|  | <b><u>1,013,131</u></b> | <b><u>703,645</u></b>   |
| <b>Excess of income over expenditure</b> | <b><u>(149,067)</u></b> | <b><u>(207,240)</u></b> |

**CANCER PREVENTION RESEARCH TRUST**

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 30 JUNE 2024

---